LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Smith & Nephew PLC ADR

Uždarymo kaina

28.69 -2.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.64

Max

29.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-18M

196M

Pardavimai

156M

3B

P/E

Sektoriaus vid.

30.957

54.533

Dividendų pajamingumas

2.58

Pelno marža

6.571

Darbuotojai

17,349

EBITDA

197M

717M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-0.31% downside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.58%

2.41%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-208M

13B

Ankstesnė atidarymo kaina

30.94

Ankstesnė uždarymo kaina

28.69

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-21 23:25; UTC

Karštos akcijos

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

2025-05-21 21:57; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

2025-05-21 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Operations in Uruguay

2025-05-21 21:01; UTC

Pagrindinės rinkos jėgos

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

2025-05-21 20:51; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

2025-05-21 23:49; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

2025-05-21 23:37; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

2025-05-21 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

2025-05-21 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

2025-05-21 23:28; UTC

Uždarbis

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

2025-05-21 23:27; UTC

Uždarbis

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-21 21:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

2025-05-21 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Ops in Uruguay

2025-05-21 21:07; UTC

Svarbiausios naujienos

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

2025-05-21 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

2025-05-21 20:59; UTC

Svarbiausios naujienos

Walmart to Cut 1,500 Jobs -- WSJ

2025-05-21 20:52; UTC

Uždarbis

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

-0.31% į apačią

12 mėnesių prognozė

Vidutinis 29.32 USD  -0.31%

Aukščiausias 30.7 USD

Žemiausias 28 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

1

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.